Page 39 - BRAND BOOK FIXAPROST

f LTFC vs monotherapy

Fixed combination of latanoprost and timolol vs individual
components for POAG or OHTH

Eve J. Higginbotham et al. Arch Ophthalmol 2002
Methods
• A 12-week, randomized, parallel-group study,
• 338 patients divided in 3 groups: LTFC on evening, L on evening and T
on morning
• 3 time points: 8 am, 10 am, 4 Ocular Hypotensive Effects and Safety
over 3 Months of Switching from an Unfixed Combination to Latanoprost
0.005%/Timolol Maleate 0.5% Fixed Combination
• Inoue et al. Journal of ocular pharmacology and therapeutics, 2011
• pm (at weeks 2, 6, 12)

Key messages:
• FCLT superior to both monotherapies in reducing mean diurnal IOP
levels, and patients treated with FCLT were significantly more likely to
achieve prespecified IOPs and IOP percentage reductions from baseline,
especially at the upper thresholds. Well tolerated.

- DIFFERENCE IN MEAN IOP REDUCTION -
Preserved latanoprost/timolol FC (n=129) Preserved latanoprost/timolol FC (n=129) data Scientific
VS latanoprost 0.05% VS timolol 0.5%
(n=134) (n=131)
P<0.002 P<0.001
Week 12 at 10 am Week 12 at 10 am

-1.51 mmHg -2.64 mmHg

BETTER DIURNAL IOP REDUCTION THAN
LATANOPROST OR TIMOLOL ALONE
f 39